You are here: Industry Insights > mRNA

News List

Merck acquires Germany-based CDMO, AmpTec expresspharma
January 08, 2021
The acquisition to expand Merck’s lipid manufacturing expertise and mRNA capabilities for vaccines, treatments and diagnostics.
eTheRNA Extends mRNA Production Services contractpharma
November 05, 2020
In response to growing international demand, eTheRNA has extended its mRNA production services to include high throughput research grade mRNA in addition to its GMP capabilities.
Rentschler Biopharma Enters COVID-19 Vax Agreement with BioNTech contractpharma
October 10, 2020
Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has entered an agreement to serve as CDMO partner for BioNTech.
BioNTech to acquire Novartis site for Covid-19 vaccine production pharmaceutical-technology
September 21, 2020
BioNTech has signed a share purchase agreement with Novartis to acquire a manufacturing site to boost its messenger RNA (mRNA)-based BNT162 Covid-19 vaccine candidate production capacity.
BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production contractpharma
September 18, 2020
Will accelerate BioNTech’s efforts to scale-up commercial manufacturing capacity for its mRNA COVID-19 vaccine candidate BNT162.
COVID-19 vaccines need novel approaches to ensure best balance of safety and efficacy: GlobalData expresspharma
August 27, 2020
AstraZeneca’s AZD-1222 and Moderna’s mRNA-1273 are currently the most promising vaccine candidates, it states.
Maravai LifeSciences Expands CDMO Capabilities at TriLink contractpharma
August 26, 2020
To increase small molecule manufacturing capacity for additional scale-up of CleanCap messenger RNA capping technology for vaccine and therapeutic programs.
Scientists decode how coronavirus molecules camouflage in host cell expresspharma
July 27, 2020
According to the researchers, this development may pave the way for the design of new drugs against the novel coronavirus SARS-CoV-2, and other emerging coronavirus infections.
GSK Buys 10% Stake in German Vaccine Developer CureVac contractpharma
July 22, 2020
Companies will collaborate on the research and development mRNA vaccine candidates.
GSK to obtain 10% stake in vaccines maker CureVac for $163m pharmaceutical-technology
July 21, 2020
GlaxoSmithKline (GSK) has signed an agreement with German company CureVac to research, develop, manufacture and commercialise up to five mRNA-based vaccines and monoclonal antibodies (mAbs) against infectious diseases.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page